Brilacidin Dosing & Reconstitution Guide

Brilacidin can be administered via two primary routes: intravenous (IV) for systemic effects and topical for localized applications. In clinical trials, particularly the Phase 2 studies targeting acute bacterial skin and skin structure infections (ABSSSI), the recommended dosing frequency for IV administration was once daily. The dose range identified for this route was 0.6 mg/kg/day, which was found to be effective in the studied population. Additionally, while topical formulations of Brilacidin have also been explored, specific dosing parameters for these applications may differ and require further investigation. It is essential for researchers to consider these variables when designing experiments and to remain aware of the specific context of dosing as reported in clinical trials.

The safety profile of Brilacidin was evaluated in a Phase II trial focusing on ABSSSI, which indicated that the compound was generally well-tolerated among participants. However, some infusion-related reactions were noted during IV administration, alongside instances of elevated creatine phosphokinase levels in certain subjects, which may warrant further investigation. As with any investigational compound, specific contraindications have been identified; these include known hypersensitivity to Brilacidin, severe renal impairment—where data on renal clearance is limited—and the absence of safety data in pregnant or breastfeeding individuals. Researchers must consider these factors when planning studies to ensure participant safety and compliance with ethical standards.